Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emily Egeler"'
Autor:
Audrey Mauguen, Snehit Prabhu, Christine L Phillips, Kevin J. Curran, Michael Kunicki, Prakash Satwani, Theodore W. Laetsch, Rachel Wilcox, Muna Qayed, Vasant Chinnabhandar, Crystal L. Mackall, Steven P. Margossian, Michael R. Verneris, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Julie-An An Talano, Emily Egeler, Gary Doug Myers, A. Yasemin Goksenin, Amy Moskop, Cara A Rabik, Holly L Pacenta, Amy K. Keating, Jenna Rossoff, Christa Krupski, Heather E. Stefanski, Patrick A. Brown, Nicole Karras, Jaap Jan Boelens, Sharon Mavroukakis, Liora M. Schultz
Publikováno v:
Blood advances, vol 6, iss 7
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5a5590ca98bdc6c2ccd6b052b9feb
https://escholarship.org/uc/item/6xt142fk
https://escholarship.org/uc/item/6xt142fk
Autor:
Michael Kunicki, Sharon Mavroukakis, Cara A Rabik, Christine L Phillips, Amy K. Keating, Jenna Rossoff, Christa Krupski, Rachel Wilcox, Amy Moskop, Adam Lane, Nicole Karras, Kevin J. Curran, A. Yasemin Goksenin, Crystal L. Mackall, Vasant Chinnabhandar, Emily Egeler, Heather E. Stefanski, Michelle L. Hermiston, Julie-An An Talano, Theodore W. Laetsch, Gary Doug Myers, Prakash Satwani, Snehit Prabhu, Christina Baggott, Steven P. Margossian, Patrick A. Brown, Muna Qayed, Vanessa A Fabrizio, Holly L Pacenta, Michael R. Verneris, Liora M. Schultz
Publikováno v:
Blood Advances
Key Points CD19 CAR therapy for R/R EM disease, particularly CNS, offers a beneficial option with similar toxicity and survival to BM disease.There was no increased cytokine release syndrome or neurotoxicity in patients with R/R EM disease, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5643a68fa7ec55f29728456a9d6f1876
https://escholarship.org/uc/item/1g83m8ch
https://escholarship.org/uc/item/1g83m8ch
Autor:
Courtney Erickson, Sharon Mavroukakis, Lindsey Rasmussen, Emily Egeler, Rebecca Richards, Sonia Partap, John S. Tamaresis, Aaron Mochizuki, Anne Cunniffe Marcy, Kristen W. Yeom, Jennifer Moon, Harshini Chinnasamy, Steven A. Feldman, Gerald A. Grant, Zach Ehlinger, Crystal L. Mackall, Agnes Reschke, Christina Baggot, Paul G. Fisher, Liora M. Schultz, Shabnum Patel, Kayla Landrum, Zina Good, Michelle Monje, Cynthia J. Campen, Michael Kunicki, Michelle Celones, Timothy T. Cornell, Jasia Mahdi, Sreevidya Kurra, Hannes Vogel, Robbie G. Majzner, Valentin Barsan, Kara L. Davis, Bita Sahaf, Angus Toland, Sneha Ramakrishna
Publikováno v:
Neuro-Oncology
Introduction We are conducting a Phase I clinical trial utilizing chimeric antigen receptor (CAR) T-cells targeting GD2 (NCT04196413) for H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) and spinal cord diffuse midline glioma (DMG). Cerebrospina